AR128688A1 - Anticuerpos anti-cd39 y uso de los mismos - Google Patents

Anticuerpos anti-cd39 y uso de los mismos

Info

Publication number
AR128688A1
AR128688A1 ARP230100529A ARP230100529A AR128688A1 AR 128688 A1 AR128688 A1 AR 128688A1 AR P230100529 A ARP230100529 A AR P230100529A AR P230100529 A ARP230100529 A AR P230100529A AR 128688 A1 AR128688 A1 AR 128688A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
chain variable
complementarity determining
Prior art date
Application number
ARP230100529A
Other languages
English (en)
Spanish (es)
Inventor
Christine Elizabeth Bowman
Ada Pei Xian Chen
Ester Fernandez-Salas
Nigel Pelham Clinton Walker
Xiaoning Zhao
Yaohua Hu
Siwei Nie
Jijie Gu
Original Assignee
Arcus Biosciences Inc
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2022/079021 external-priority patent/WO2023164872A1/en
Application filed by Arcus Biosciences Inc, Wuxi Biologics Ireland Ltd filed Critical Arcus Biosciences Inc
Publication of AR128688A1 publication Critical patent/AR128688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP230100529A 2022-03-03 2023-03-02 Anticuerpos anti-cd39 y uso de los mismos AR128688A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2022/079021 WO2023164872A1 (en) 2022-03-03 2022-03-03 Anti-cd39 antibodies and use thereof
CN2022126070 2022-10-19

Publications (1)

Publication Number Publication Date
AR128688A1 true AR128688A1 (es) 2024-06-05

Family

ID=87883061

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100529A AR128688A1 (es) 2022-03-03 2023-03-02 Anticuerpos anti-cd39 y uso de los mismos

Country Status (13)

Country Link
US (2) US11970543B2 (cg-RX-API-DMAC7.html)
EP (1) EP4486785A4 (cg-RX-API-DMAC7.html)
JP (2) JP7712496B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240156633A (cg-RX-API-DMAC7.html)
CN (2) CN119173535A (cg-RX-API-DMAC7.html)
AR (1) AR128688A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023227964A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253669A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002620A1 (cg-RX-API-DMAC7.html)
IL (1) IL315351A (cg-RX-API-DMAC7.html)
MX (1) MX2024010646A (cg-RX-API-DMAC7.html)
TW (1) TW202340243A (cg-RX-API-DMAC7.html)
WO (1) WO2023165561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260191954A1 (en) * 2022-12-01 2026-07-09 Innate Pharma Compositions and methods for neoadjuvant treatment in cancer
CN119798442B (zh) * 2023-12-27 2025-12-16 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US10556959B2 (en) * 2014-11-07 2020-02-11 Xencor, Inc. Anti-CD39 antibodies and uses thereof
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
US11376269B2 (en) 2016-05-06 2022-07-05 Inserm Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
AU2018346447B2 (en) 2017-10-06 2025-06-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
IL273440B1 (en) 2017-11-15 2026-08-01 Innate Pharma Strengthening the effect of ATP release
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
EP3806902A4 (en) 2018-06-14 2022-05-04 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
MX2021010119A (es) 2019-02-21 2021-12-10 Trishula Therapeutics Inc Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
WO2021203058A2 (en) 2020-04-03 2021-10-07 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
US20240052061A1 (en) 2020-09-10 2024-02-15 Purinomia Biotech, Inc. Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
EP4251650A4 (en) 2020-11-27 2024-10-23 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta

Also Published As

Publication number Publication date
CA3253669A1 (en) 2023-09-07
IL315351A (en) 2024-11-01
CN119569881A (zh) 2025-03-07
US20240034803A1 (en) 2024-02-01
AU2023227964A1 (en) 2024-09-19
JP2025508956A (ja) 2025-04-10
CN119173535A (zh) 2024-12-20
US11970543B2 (en) 2024-04-30
JP2025148452A (ja) 2025-10-07
TW202340243A (zh) 2023-10-16
WO2023165561A1 (en) 2023-09-07
EP4486785A1 (en) 2025-01-08
CN119569881B (zh) 2025-11-07
KR20240156633A (ko) 2024-10-30
EP4486785A4 (en) 2026-07-08
JP7712496B2 (ja) 2025-07-23
CL2024002620A1 (es) 2025-01-03
MX2024010646A (es) 2024-09-19
US20250084178A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
AR126987A2 (es) Inmunoconjugados
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
AR111207A1 (es) Anticuerpos anti-lag3
MX2022013513A (es) Bibliotecas de ácidos nucleicos variantes para coronavirus.
PE20190514A1 (es) Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123
WO2023023183A3 (en) Sars-cov-2 antibodies and related compositions and methods of use
WO2022271884A3 (en) Methods and compositions relating to covid antibody epitopes
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
AR110755A1 (es) Anticuerpos dirigidos a hueso
Jarray et al. Disruption of phactr-1 pathway triggers pro-inflammatory and pro-atherogenic factors: New insights in atherosclerosis development
AR129991A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
AR093186A1 (es) Proteinas de union al antigeno cd27l
BR112022011357A2 (pt) Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
WO2023076420A3 (en) Multispecific sars-cov-2 antibodies and methods of use
PE20220489A1 (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso
AU2020270920A1 (en) Recombinant elastin and production thereof
Mojtahedi et al. Leishmania major: identification of developmentally regulated proteins in procyclic and metacyclic promastigotes
AR130550A1 (es) Anticuerpo anti-il-1r3 humanizado y métodos de uso
CN104232588A (zh) 一种抗肝纤维化药物高通量筛选细胞模型的构建及应用
AR123728A1 (es) Anticuerpos cd1a y su uso
Ayón-Núñez et al. Identification and characterization of Taenia solium enolase as a plasminogen-binding protein
AR124289A1 (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos
Mukai et al. Discovery of mitocryptide-1, a neutrophil-activating cryptide from healthy porcine heart
Rivard et al. Expression of the calcium-binding protein S100A4 is markedly up-regulated by osmotic stress and is involved in the renal osmoadaptive response